Wells Fargo & Company Evoke Pharma Inc Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Evoke Pharma Inc stock. As of the latest transaction made, Wells Fargo & Company holds 66 shares of EVOK stock, worth $31. This represents 0.0% of its overall portfolio holdings.
Number of Shares
66
Previous 26
153.85%
Holding current value
$31
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding EVOK
# of Institutions
16Shares Held
3.16MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD847KShares$397,8850.21% of portfolio
-
Bleichroeder LP New York, NY825KShares$387,7500.16% of portfolio
-
Altium Capital Management LP New York, NY725KShares$340,7220.25% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT675KShares$317,2500.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.9KShares$14,0290.0% of portfolio
About Evoke Pharma Inc
- Ticker EVOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 3,343,070
- Market Cap $1.57M
- Description
- Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabeti...